Eight-year follow-up of olanzapine therapy in a previous treatment-refractory schizophrenic patient: A case report

Pinkhas Sirota, Reuben Benhatov

Research output: Contribution to journalArticlepeer-review

Abstract

The introduction of atypical antipsychotic drugs during the 1990s represented a great step forward in the treatment of schizophrenia and other psychoses. These drugs might more effectively prevent relapse because of their effectiveness against a wider range of schizophrenic symptoms, as well as their improved tolerability, which leads to improved medication compliance. Olanzapine, a thienobenzodiazapine, is an antipsychotic drug with high affinity for the serotonergic receptors 5-HT2 and 5-HT6 and high affinity for dopaminergic receptors, mainly D2, D3 and D4, and with a lower propensity to cause extrapyramidal symptoms or increasing prolactin levels. The long-term efficacy and safety of olanzapine for treating treatment-refractory schizophrenia is still being investigated. The authors present a case of a 43-year-old man suffering from chronic treatment-resistant schizophrenia with both positive and negative symptoms, who was successfully treated with olanzapine for 8 years.

Original languageEnglish
Pages (from-to)211-214
Number of pages4
JournalInternational Journal of Psychiatry in Clinical Practice
Volume6
Issue number4
DOIs
StatePublished - Dec 2002

Keywords

  • Atypical antipsychotics
  • Long follow-up of schizophrenia
  • Olanzapine
  • Treatment-refractory schizophrenia

Fingerprint

Dive into the research topics of 'Eight-year follow-up of olanzapine therapy in a previous treatment-refractory schizophrenic patient: A case report'. Together they form a unique fingerprint.

Cite this